Why Wall Street Got Anthropic’s Big DNA Discovery So Wrong

On September 23 Anthropic said Claude had found something new in biology. Roughly 950 agents spent 21 hours and 210 million tokens hunting through genetic databases, working down from more than 200,000 known genes to 3,500 arrangements worth a second look, and then to the 20 most promising. One of the 20 was a layout no published study had described: DNA repeats spaced at regular intervals, with genes sitting alongside. Claude measured the spacing, compared it against known systems and searched the literature for any earlier report. The layout resembled the architecture CRISPR is built on, which is why it caught their eye.

CRISPR is gene-editing technology: it finds one exact spot in a genome of three billion letters and changes what is written there. Control-F and Control-V, for DNA.

Gene-editing stocks fell the same day. Prime Medicine dropped 11.58%, Beam Therapeutics 6.02% and CRISPR Therapeutics 5.54%. Biotech was having a bad day regardless, with the 10-year Treasury yield pushing above 5.11% that afternoon, its highest since 2007, and selling running across the sector. So the prices can’t tell us how much of that was Claude, but the headlines made the connection anyway.

That reflex is becoming routine. In February, when Anthropic released a model it said could produce the kind of financial analysis that normally takes people days, FactSet fell as much as 10% on the day, S&P Global 4.7% and Moody’s 2.9%. In July, when OpenAI launched Presence, its agent product for corporate workflows, the IGV software index dropped 3% before the day was out. Each time a sector was marked down within hours of a company blog post.

The difference this week is that there was nothing to buy. In February and July there was a product on the other end of the selloff, and on Wednesday there was a finding whose function Anthropic can’t really name — it can’t say what the system Claude found actually does, and says the work to find out is ongoing.